IQVIA (NYSE:IQV) Upgraded by Wall Street Zen to Buy Rating

IQVIA (NYSE:IQV) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Sunday.

Several other research firms have also issued reports on IQV. Evercore ISI upped their target price on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. UBS Group lifted their target price on IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. BMO Capital Markets initiated coverage on shares of IQVIA in a research report on Thursday, November 13th. They set an “outperform” rating and a $260.00 price target for the company. Finally, Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.06.

IQVIA Stock Performance

NYSE IQV opened at $235.20 on Friday. The company has a fifty day moving average price of $229.10 and a 200-day moving average price of $205.90. The firm has a market cap of $40.05 billion, a price-to-earnings ratio of 32.26, a PEG ratio of 2.39 and a beta of 1.36. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA has a 1 year low of $134.65 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities research analysts predict that IQVIA will post 10.84 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Verdence Capital Advisors LLC bought a new stake in IQVIA during the 2nd quarter valued at $3,612,000. Amundi grew its holdings in IQVIA by 46.3% in the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after acquiring an additional 405,250 shares during the last quarter. Diversified Trust Co increased its position in shares of IQVIA by 57.2% in the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock valued at $8,087,000 after acquiring an additional 15,487 shares during the period. Act Two Investors LLC bought a new position in shares of IQVIA during the second quarter valued at about $26,528,000. Finally, Oregon Public Employees Retirement Fund boosted its holdings in shares of IQVIA by 37.1% during the third quarter. Oregon Public Employees Retirement Fund now owns 19,463 shares of the medical research company’s stock worth $3,697,000 after purchasing an additional 5,271 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.